Vertex Pharma (VRTX) Tops Q4 EPS by 24c, Revenues Beat; Offers FY19 Revenue Guidance
Vertex Pharma (NASDAQ: VRTX) reported Q4 EPS of $1.30, $0.24 better than the analyst estimate of $1.06. Revenue for the quarter came in at $868 million versus the consensus estimate of $819.12 million.
"Our achievements in 2018 were marked by a significant increase in the number of CF patients being treated with our approved medicines and by remarkable progress advancing our two triple combination regimens through late-stage development. We remain on track to submit a New Drug Application for a triple combination regimen no later than mid-2019," said Jeffrey Leiden, M.D., Ph.D., Chairman, President and Chief Executive Officer of Vertex. "Beyond CF, we have made tremendous advances with our research and development pipeline. We initiated clinical development for potential medicines to treat alpha-1 antitrypsin deficiency, sickle cell disease and beta thalassemia, provided multiple positive data readouts in pain, and progressed several other drug candidates into late preclinical development. Through our continued progress in treating CF and other serious diseases, we believe Vertex will continue to create revenue and earnings growth in 2019 and beyond."
GUIDANCE:
Vertex Pharma sees FY2019 revenue of $3.45-3.55 billion, versus the consensus of $3.55 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.